Treatment of obstructive airway disease with a cysteine donor protein supplement: A case report

Chest

Volumn 117, Issue 3, 2000, Pages 914-916

  Lothian, Bryce ^a   Grey, Vijaylaxmi ^a   Kimoff, R John ^b   Lands, Larry C ^a  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Glutathione; Inflammation; Oxidative stress; Supplementation

Indexed keywords

CORTICOSTEROID; CYSTEINE; GLUTATHIONE; HMS 90; IMMUNOCAL; M PROTEIN; SALBUTAMOL; UNCLASSIFIED DRUG;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CASE REPORT; DIET SUPPLEMENTATION; DRUG EFFECT; FEMALE; HUMAN; INFLAMMATION; LUNG FUNCTION; OBSTRUCTIVE AIRWAY DISEASE; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 0034118330     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.3.914     Document Type: Article

References (19)

1. 1 Powell CV, Nash AA, Powers HJ, et al. Antioxidant status in asthma. Pediatr Pulmonol 1994; 18:34-38
2. 2 Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease: Oxidative Stress Study Group. Am J Respir Crit Care Med 1997; 156:341-357
3. 3 Anderson ME. Glutathione and glutathione delivery compounds. Adv Pharmacol 1997; 38:65-78
4. 4 Meister A. Metabolism and function of glutathione. In: Dolphin D, Poulsen R, Avramovic O, eds. Glutathione: chemical, biochemical, and medical aspects. New York, NY: John Wiley and Sons, 1989; 367-474
5. 5 Marrades RM, Roca J, Barbera JA, et al. Nebulized glutathione induces bronchoconstriction in patients with mild asthma. Am J Respir Crit Care Med 1997; 156:425-430
6. 6 Lands LC, Grey VL, Smountas AA, et al. Lymphocyte glutathione levels in children with cystic fibrosis. Chest 1999; 116:201-205
7. 7 Lands LC, Grey VL, Smountas AA. Effect of supplementation with a cysteine donor on muscular performance. J Appl Physiol 1999; 87:1381-1385
8. 8 Anderson ME, Meister A. Transport and direct utilization of gamma-glutamylcyst(e)ine for glutathione synthesis. Proc Natl Acad Sci USA 1983; 80:707-711
9. 9 Richie JP Jr, Abraham P, Leutzinger Y. Long-term stability of blood glutathione and cysteine in humans. Clin Chem 1996; 42:1100-1105
10. 10 Heffner JE, Repine JE. Pulmonary strategies of antioxidant defense. Am Rev Respir Dis 1989; 140:531-547
11. 11 Cantin A, North S, Hubbard R, et al. Normal epithelial lining fluid contains high levels of glutathione. J Appl Physiol 1987; 63:152-157
12. 12 Peterson JD, Herzenberg LA, Vasquez K, et al. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci USA 1998; 95:3071-3076
13. 13 Flohe L, Brigelius-Flohe R, Saliou C, et al. Redox regulation of NF-kappa B activation. Free Radic Biol Med 1997; 22:1115-1126
14. 14 Palombella VJ, Rando OJ, Goldberg AL, et al. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994; 78:773-785
15. 15 Rahman I, Macnee W. Role of transcription factors in inflammatory lung diseases. Thorax 1998; 53:601-612
16. 16 Hull J, Vervaart P, Grimwood K, et al. Pulmonary oxidative stress response in young children with cystic fibrosis. Thorax 1997; 52:557-560
17. 17 Hubbard RC, Ogushi F, Fells GA, et al. Oxidants spontaneously released by alveolar macrophages of cigarette smokers can inactivate the active site of alpha 1-antitrypsin, rendering it ineffective as an inhibitor of neutrophil elastase. J Clin Invest 1987; 80:1289-1295
18. 18 Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320:365-376
19. 19 Koch SM, Leis AA, Stokic DS, et al. Side effects of intravenous N-acetylcysteine [abstract]. Am J Respir Crit Care Med 1994; 149:A321